OP0083 ANAKINRA PLUS STANDARD OF CARE FOR THE REDUCTION OF HYPERINFLAMMATION AND RESPIRATORY DISTRESS IN PATIENTS WITH SARS-COV-2 INFECTION: A MULTICENTRE, RANDOMISED, OPEN-LABEL PHASE 2/3 TRIAL (ANA-COVID-GEAS STUDY) | Publicación